CPDR Updates Its Prostate Cancer Website

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

ROCKVILLE, Maryland-The website for the Center for Prostate Disease Research (CPDR) has a whole new look. Stephen Doyle, an experienced graphic artist, has updated and redesigned the site to be a user-friendly tool for patients, clinicians, scientists, and the general public to find information about prostate cancer and related diseases.

ROCKVILLE, Maryland—The website for the Center for Prostate Disease Research (CPDR) has a whole new look. Stephen Doyle, an experienced graphic artist, has updated and redesigned the site to be a user-friendly tool for patients, clinicians, scientists, and the general public to find information about prostate cancer and related diseases.

CPDR director Judd W. Moul, MD, a colonel in the Army Medical Department, commented, "Previously, the content was sound, but there was not as much in terms of presentation. Now, my patients say that it has great readability and visual appeal." To visit the CPDR website, go to www.cpdr.org. 

Articles in this issue
Elderly Colon Cancer Patients Benefit From Adjuvant Chemotherapy
Stromal Cells May Be Involved in Development of Breast Carcinoma
Intercultural Facts About Cancer
Nurse-Provided Education Crucial to Sural Nerve Graft Prostatectomy Patients
18-Gene Cluster Found in ER-Positive Breast Cancers
Viread OK’d for Treating HIV With Other Antiretrovirals
Surgeons in New York Operate on Patient in France
Fulvestrant Reduces Cell Turnover Index More Than Tamoxifen
New Lung Cancer Campaign Launched
CPDR Updates Its Prostate Cancer Website
NIAID Begins Phase I Trial of a DNA-Based HIV Vaccine
PET Used to Measure Efficacy of an Angiogenesis Inhibitor
Avon Donates $20 Million to NCI for Cancer Research
Weekly Gemcitabine/Vinorelbine Proves Effective in NSCLC
Supplemental NDA Submitted for Gleevec
Recent Videos
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content
Carotuximab/Apalutamide Improves PFS in Previously Treated Metastatic CRPC

Carotuximab/Apalutamide Improves PFS in Previously Treated Metastatic CRPC

Ariana Pelosci
September 24th 2025
Article

In an interim safety analysis, no dose-limiting toxicities, unexpected AEs, or grade 3/4 AEs were reported in 10 patients treated for metastatic CRPC.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?

How Will Gemcitabine Intravesical System Impact BCG-Unresponsive NMIBC?

Ariana Pelosci
September 16th 2025
Article

Gary Steinberg, MD, highlights the FDA approval of the gemcitabine intravesical system and what this means for patients with BCG-unresponsive NMIBC.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.

Benmelstobart Combo Elicits PFS Advantage in Untreated Advanced ccRCC

Roman Fabbricatore
September 5th 2025
Article

Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.

External validation will be assessed in cohort 2 of the AURORAX-0087A trial to improve recurrence detection for clear cell renal cell carcinoma.

Urine Glycosaminoglycan Scores Show High Sensitivity to Detect ccRCC

Roman Fabbricatore
September 3rd 2025
Article

External validation will be assessed in cohort 2 of the AURORAX-0087A trial to improve recurrence detection for clear cell renal cell carcinoma.